Abstract
Report description
The Partnering with Bigpharma: The Definitive Guide to Bigpharma Partnering
Interests, Contacts and Agreements report provides the most comprehensive and
in-depth insight into the dealmaking interests and activity of the worlds
leading fifty biopharma companies. This premier report provides all the
information you require to better understand bigpharma partnering.
One of the key aspects of partnering is finding those companies that are
potential candidates for the development and commercialization of the next
generation of therapies. A lot of resources are spent on finding partners,
identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their
partnering activities to deliver the company' s business development
objectives. Over 200 charts allow quick understanding of each bigpharma
companies dealmaking trends over the last four years.
This report contains over 1,200 links to online copies of actual contract
documents as submitted to the Securities Exchange Commission by bigpharma and
their partners.
Contract documents provide the answers to numerous questions about a
prospective partner' s flexibility on a wide range of important issues, many of
which will have a significant impact on each party' s ability to derive value
from the deal.
The initial Chapters of this report provide an orientation of bigpharma' s
dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst Chapter
2 lists the top 50 leading biopharma companies based on 2006
pharmaceutical revenues and dealmaking activity since 2005.
Chapter 3 analyzes the most active dealmakers since 2005 in M&A and
partnering deals announced, whilst Chapter 4 analyzes the top deals of
2005-8 according to reported deal size.
Chapter 5 provides a summary on best practice on how to submit an
opportunity to bigpharma, to ensure building of relationships and to obtain a
prompt assessment and response from the business development function of the
prospective partner.
Chapter 6 lists forthcoming partnering events where valuable face to
face meetings with bigpharma provide a highly effective means of obtaining
interest in novel opportunities. These events are where dealmaking gets
initiated through numerous back to back meetings.
The main body of the report is provided in Chapter 7 and 8.
Firstly, a series of matrices provide a cross reference for each bigpharma
company versus therapy area with respect to marketed and pipeline activity,
partnering interests, and partnering activity in the last two years.
Secondly, in-depth profiles of every bigpharma company provide everything
required to assess the suitability of a company as a prospective partner. This
includes a company overview, detailed analysis of the company' s marketed and
pipeline disease targets, partnering interests, partnering activity according
to deal type, phase of development, therapy area. Each profile also includes
in-depth contact information for individuals within the business development
function.
Key benefits
Partnering with Bigpharma provides the user with the following key benefits:
- Detailed company profiles for each of the top 50 bigpharma companies
- Over 200 charts showing a company' s dealmaking activity since 2005,
allowing quick identification potential partners
- In-depth marketed and pipeline product activity of each company
- Partnering interests and therapy focus revealed
- Partnering activity since 2000 - number of deals per year
- Partnering activity for 2005-2008
- Activity by deal type
- Activity by phase of development
- Activity by therapeutic area
- List of recent partner companies
- Comprehensive access to over 1,200 actual contracts entered into by the
leading fifty biopharma companies*
- Insight into the terms included in a partnering agreement, together with
real world clause examples
- Understand the key deal terms the company has agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
*Subject to being published via regulatory requirements of the Securities
Exchange Commission.
Report scope
Partnering with Bigpharma is intended to provide the reader with an in-depth
understanding of the partnering activities and interests of the leading fifty
biopharma companies worldwide, enabling the effective assessment and selection
of partners of choice, based on the latest knowledge of a company' s approach
to partnering.
Partnering with Bigpharma includes:
- Detailed company profiles for each of the top 50 bigpharma companies,
including:
- Full contact details
- Business developer contact details including name, title, email and
telephone (where available)
- Marketed indications
- Pipeline indications
- Partnering interests and indications
- Partnering activity since 2000
- Current partner companies since 2005
- Partnering activity since 2005 by:
- Deal type
- Stage of development
- Therapy area
- Over 200 charts showing the dealmaking activity of each company since 2005
- The tools to enable effective and efficient preparation for partnering
negotiation with bigpharma
- Listing of over 1,200 contract documents between bigpharma and partner
companies
- The leading M&A and partnering deals by value 2005-8
- Most active M&A and partnering dealmakers 2005-8
The Partnering with Bigpharma report also provides comprehensive access to
available contract documents for each of the fifty bigpharma companies.
Analyzing actual company agreements allows assessment of the following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subscontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal
type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
For each company in Partnering with Bigpharma report, the available contracts
are listed by deal type, including:
- Co-development
- Co-marketing
- Co-promotion
- Collaborative R&D
- Development
- Distribution
- Joint venture
- Licensing
- M&A
- Manufacturing
- Marketing
- Promotion
- Research
- Supply
Number of pages:
The report is comprised of 648 pages.
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Bigpharma - The Top 50
Chapter 3 - Most active bigpharma dealmakers
- 3.1 Bigpharma M&A activity
- 3.2 Bigpharma partnering
Chapter 4 - Top bigpharma deals - 2000-7
- 4.1 Bigpharma M&A
- 4.2 Bigpharma partnering
Chapter 5 - Submitting Opportunities to Bigpharma
- 5.1 How to submit an opportunity
- 5.2 Opportunity submission template
- 5.3 Sending emails
- 5.4 Face to face at partnering events
- 5.5 Online submission forms
Chapter 6 - Forthcoming bigpharma partnering events
Chapter 7 - Bigpharma company - therapy locator
- 7.1 How to use the therapy matrix tables
- 7.2 Therapeutic area definitions
- 7.3 Bigpharma - Therapeutic target matrix - marketed and pipeline
compounds
- 7.5 Bigpharma - Therapeutic target matrix - expressed partnering
interests
- 7.6 Bigpharma - Therapeutic target matrix - recent deals - 2005-2007
Chapter 8 - Bigpharma Company Profiles
- 8.1 How to use company profiles
- 8.2 Field definitions
- 8.3 Company profiles
- Abbott
- Actavis
- Allergan
- Amgen
- Astellas
- AstraZeneca
- Barr Pharmaceuticals
- Baxter International
- Bayer
- Biogen Idec
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Chugai
- CSL
- Daiichi Sankyo
- Eisai
- Eli Lilly
- Forest Laboratories
- Genentech
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- King
- Lundbeck
- Menarini
- Merck & Co
- Merck Serono KGaA
- Mitsubishi-Tanabe
- Mundipharma
- Novartis AG
- Novo Nordisk
- Nycomed Pharma
- Otsuka
- Pfizer
- Procter & Gamble
- Ratiopharm
- Roche
- Sanofi-Aventis
- Schering Plough
- Servier
- Shire
- Solvay
- Stada
- Takeda
- Teva
- UCB
- Watson
- Wyeth
About Current Partnering
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Report Update Subscription
Order form - Company Dealmaking Profiles
Order Form - CD-Rom
Figures in report
- Figure 1: Bigpharma - top 50 by pharma revenues 2007
- Figure 2: Leading Bigpharma M&A companies, 2005-7
- Figure 3: Leading Bigpharma partnering companies, 2005-7
- Figure 4: Leading M&A deals involving bigpharma by value, 2005-7
- Figure 5: Leading partnering deals by value, 2005-7
- Figure 6: Typical partnering opportunity submission template
- Figure 7: Partnering events 2008-9
- Figure 8: Therapeutic area definitions
- Figure 9: Therapeutic target matrix - marketed and pipeline compounds
- Figure 10: Therapeutic target matrix - expressed partnering interests
- Figure 11: Therapeutic target matrix - recent deals 2005-7
- Figure 12: Company profile template and definitions used in report
- Figure 13: Abbott - Dealmaking frequency 2000-2007
- Figure 14: Abbott - recent deals (2005-2008) by deal type
- Figure 15: Abbott - recent deals (2005 - 2008) by stage of development
- Figure 16: Abbott - recent deals (2005 - 2008) by therapy area
- Figure 17: Recent Abbott partnering deals (2003-2008) where contract
document available
- Figure 18: Actavis - Dealmaking frequency 2000-2007
- Figure 19: Actavis - recent deals (2005-2008) by deal type
- Figure 20: Actavis - recent deals (2005 - 2008) by stage of development
- Figure 21: Actavis - recent deals (2005 - 2008) by therapy area
- Figure 22: Recent Actavis partnering deals (2003-2008) where contract
document available
- Figure 23: Alcon Labs dealmaking frequency 2000-2007
- Figure 24: Alcon Labs - recent deals (2005 - 2008) by deal type
- Figure 25: Alcon Labs - recent deals (2005 - 2008) by stage of development
- Figure 26: Alcon Labs - recent deals (2005 - 2008) by therapy area
- Figure 27: Recent Alcon Labs partnering deals (2003-2008) where contract
document available
- Figure 28: Allergan - Dealmaking frequency 2000-2007
- Figure 29: Allergan - recent deals (2005-2008) by deal type
- Figure 30: Allergan - recent deals (2005 - 2008) by stage of development
- Figure 31: Allergan - recent deals (2005 - 2008) by therapy area
- Figure 32: Recent Allergan partnering deals (2003-2008) where contract
document available
- Figure 33: Amgen - Dealmaking frequency 2000-2007
- Figure 34: Amgen - recent deals (2005-2008) by deal type
- Figure 35: Amgen - recent deals (2005 - 2008) by stage of development
- Figure 36: Amgen - recent deals (2005 - 2008) by therapy area
- Figure 37: Recent Amgen partnering deals (2003-2008) where contract
document available
- Figure 38: Astellas - Dealmaking frequency 2000-2007
- Figure 39: Astellas - recent deals (2005-2008) by deal type
- Figure 40: Astellas - recent deals (2005 - 2008) by stage of development
- Figure 41: Astellas - recent deals (2005 - 2008) by therapy area
- Figure 42: Recent Astellas partnering deals (2003-2008) where contract
document available
- Figure 43: AstraZeneca - Dealmaking frequency 2000-2007
- Figure 44: AstraZeneca - recent deals (2005-2008) by deal type
- Figure 45: AstraZeneca - recent deals (2005 - 2008) by stage of
development
- Figure 46: AstraZeneca - recent deals (2005 - 2008) by therapy area
- Figure 47: Recent AstraZeneca partnering deals (2003-2008) where contract
document available
- Figure 208: Barr - Dealmaking frequency 2000-2007
- Figure 219: Barr - recent deals (2005-2008) by deal type
- Figure 220: Barr - recent deals (2005 - 2008) by stage of development
- Figure 221: Barr - recent deals (2005 - 2008) by therapy area
- Figure 222: Recent Barr partnering deals (2003-2008) where contract
document available
- Figure 48: Baxter - Dealmaking frequency 2000-2007
- Figure 49: Baxter - recent deals (2005-2008) by deal type
- Figure 50: Baxter - recent deals (2005 - 2008) by stage of development
- Figure 51: Baxter - recent deals (2005 - 2008) by therapy area
- Figure 52: Recent Baxter partnering deals (2003-2008) where contract
document available
- Figure 53: Bayer - Dealmaking frequency 2000-2007
- Figure 54: Bayer - recent deals (2005-2008) by deal type
- Figure 55: Bayer - recent deals (2005 - 2008) by stage of development
- Figure 56: Bayer - recent deals (2005 - 2008) by therapy area
- Figure 57: Recent Bayer partnering deals (2003-2008) where contract
document available
- Figure 58: Biogen Idec - Dealmaking frequency 2000-2007
- Figure 59: Biogen Idec - recent deals (2005 - 2008) by deal type
- Figure 60: Biogen Idec - recent deals (2005 - 2008) by stage of
development
- Figure 61: Biogen Idec - recent deals (2005 - 2008) by therapy area
- Figure 62: Recent Biogen Idec partnering deals (2003-2008) where contract
document available
- Figure 63: Boehringer Ingelheim - Dealmaking frequency 2000-2007
- Figure 64: Boehringer Ingelheim - recent deals (2005 - 2008) by deal type
- Figure 65: Boehringer Ingelheim - recent deals (2005 - 2008) by stage of
development
- Figure 66: Boehringer Ingelheim - recent deals (2005 - 2008) by therapy
area
- Figure 67: Recent Boehringer Ingelheim partnering deals (2003-2008) where
contract document available
- Figure 68: Bristol-Myers Squibb - Dealmaking frequency 2000-2007
- Figure 69: Bristol-Myers Squibb - recent deals (2005 - 2008) by deal type
- Figure 70: Bristol-Myers Squibb - recent deals (2005 - 2008) by stage of
development
- Figure 71: Bristol-Myers Squibb - recent deals (2005 - 2008) by therapy
area
- Figure 72: Recent Bristol-Myers Squibb partnering deals (2003-2008) where
contract document available
- Figure 73: Chugai - Dealmaking frequency 2000-2007
- Figure 74: Chugai - recent deals (2005-2008) by deal type
- Figure 75: Chugai - recent deals (2005 - 2008) by stage of development
- Figure 76: Chugai - recent deals (2005 - 2008) by therapy area
- Figure 77: Recent Chugai partnering deals (2003-2008) where contract
document available
- Figure 78: CSL - Dealmaking frequency 2000-2007
- Figure 79: CSL - recent deals (2005-2008) by deal type
- Figure 80: CSL - recent deals (2005 - 2008) by stage of development
- Figure 81: CSL - recent deals (2005 - 2008) by therapy area
- Figure 82: Recent CSL partnering deals (2003-2008) where contract document
available
- Figure 208: DaiichiSankyo - Dealmaking frequency 2000-2007
- Figure 219: DaiichiSankyo - recent deals (2005-2008) by deal type
- Figure 220: DaiichiSankyo - recent deals (2005 - 2008) by stage of
development
- Figure 221: DaiichiSankyo - recent deals (2005 - 2008) by therapy area
- Figure 222: Recent DaiichSankyo partnering deals (2003-2008) where
contract document available
- Figure 83: Eisai - Dealmaking frequency 2000-2007
- Figure 84: Eisai - recent deals (2005-2008) by deal type
- Figure 85: Eisai - recent deals (2005 - 2008) by stage of development
- Figure 86: Eisai - recent deals (2005 - 2008) by therapy area
- Figure 87: Recent Eisai partnering deals (2003-2008) where contract
document available
- Figure 88: Eli Lilly - Dealmaking frequency 2000-2007
- Figure 89: Eli Lilly - recent deals (2005-2008) by deal type
- Figure 90: Eli Lilly - recent deals (2005 - 2008) by stage of development
- Figure 91: Eli Lilly - recent deals (2005 - 2008) by therapy area
- Figure 92: Recent Eli Lilly partnering deals (2003-2008) where contract
document available
- Figure 93: Forest - Dealmaking frequency 2000-2007
- Figure 94: Forest - recent deals (2005-2008) by deal type
- Figure 95: Forest - recent deals (2005 - 2008) by stage of development
- Figure 96: Forest - recent deals (2005 - 2008) by therapy area
- Figure 97: Recent Forest partnering deals (2003-2008) where contract
document available
- Figure 98: Genentech - Dealmaking frequency 2000-2007
- Figure 99: Genentech - recent deals (2005-2008) by deal type
- Figure 100: Genentech - recent deals (2005 - 2008) by stage of development
- Figure 101: Genentech - recent deals (2005 - 2008) by therapy area
- Figure 102: Recent Genentech partnering deals (2003-2008) where contract
document available
- Figure 103: Genzyme - Dealmaking frequency 2000-2007
- Figure 104: Genzyme - recent deals (2005-2008) by deal type
- Figure 105: Genzyme - recent deals (2005 - 2008) by stage of development
- Figure 106: Genzyme - recent deals (2005 - 2008) by therapy area
- Figure 107: Recent Genzyme partnering deals (2003-2008) where contract
document available
- Figure 108: Gilead - Dealmaking frequency 2000-2007
- Figure 109: Gilead - recent deals (2005-2008) by deal type
- Figure 110: Gilead - recent deals (2005 - 2008) by stage of development
- Figure 111: Gilead - recent deals (2005 - 2008) by therapy area
- Figure 112: Recent Gilead partnering deals (2003-2008) where contract
document available
- Figure 113: GlaxoSmithKline - Dealmaking frequency 2000-2007
- Figure 114: GlaxoSmithKline - recent deals (2005-2008) by deal type
- Figure 115: GlaxoSmithKline - recent deals (2005 - 2008) by stage of
development
- Figure 116: GlaxoSmithKline - recent deals (2005 - 2008) by therapy area
- Figure 117: Recent GlaxoSmithKline partnering deals (2003-2008) where
contract document available
- Figure 118: Johnson & Johnson - Dealmaking frequency 2000-2007
- Figure 119: Johnson & Johnson - recent deals (2005-2008) by deal type
- Figure 120: Johnson & Johnson - recent deals (2005 - 2008) by stage of
development
- Figure 121: Johnson & Johnson - recent deals (2005 - 2008) by therapy
area
- Figure 122: Recent Johnson & Johnson partnering deals (2003-2008) where
contract document available
- Figure 123: King Pharmaceuticals - Dealmaking frequency 2000-2007
- Figure 124: King - recent deals (2005-2008) by deal type
- Figure 125: King - recent deals (2005 - 2008) by stage of development
- Figure 126: King - recent deals (2005 - 2008) by therapy area
- Figure 127: Recent King partnering deals (2003-2008) where contract
document available
- Figure 128: Lundbeck - Dealmaking frequency 2000-2007
- Figure 129: Lundbeck - recent deals (2005-2008) by deal type
- Figure 130: Lundbeck - recent deals (2005 - 2008) by stage of development
- Figure 131: Lundbeck - recent deals (2005 - 2008) by therapy area
- Figure 132: Recent Lundbeck partnering deals (2003-2008) where contract
document available
- Figure 133: Menarini - Dealmaking frequency 2000-2007
- Figure 134: Menarini - recent deals (2005-2008) by deal type
- Figure 135: Menarini - recent deals (2005 - 2008) by stage of development
- Figure 136: Menarini - recent deals (2005 - 2008) by therapy area
- Figure 137: Recent Menarini partnering deals (2003-2008) where contract
document available
- Figure 138: Merck & Co - Dealmaking frequency 2000-2007
- Figure 139: Merck & Co - recent deals (2005-2008) by deal type
- Figure 140: Merck & Co - recent deals (2005 - 2008) by stage of
development
- Figure 141: Merck & Co - recent deals (2005 - 2008) by therapy area
- Figure 142: Recent Merck & Co partnering deals (2003-2008) where contract
document available
- Figure 143: Merck KGaA - Dealmaking frequency 2000-2007
- Figure 144: Merck KGaA - recent deals (2005-2008) by deal type
- Figure 145: Merck KGaA - recent deals (2005 - 2008) by stage of
development
- Figure 146: Merck KGaA - recent deals (2005 - 2008) by therapy area
- Figure 147: Recent Merck KGaA partnering deals (2003-2008) where contract
document available
- Figure 148: Mitsubishi-Tanabe - Dealmaking frequency 2000-2007
- Figure 149: Mitsubishi-Tanabe - recent deals (2005-2008) by deal type
- Figure 150: Mitsubishi-Tanabe - recent deals (2005 - 2008) by stage of
development
- Figure 151: Mitsubishi-Tanabe - recent deals (2005 - 2008) by therapy
area
- Figure 152: Recent Mitsubishi-Tanabe partnering deals (2003-2008) where
contract document available
- Figure 208: Mundipharma - Dealmaking frequency 2000-2007
- Figure 219: Mundipharma - recent deals (2005-2008) by deal type
- Figure 220: Mundipharma - recent deals (2005 - 2008) by stage of
development
- Figure 221: Mundipharma - recent deals (2005 - 2008) by therapy area
- Figure 222: Recent Mundipharma partnering deals (2003-2008) where contract
document available
- Figure 153: Novartis - Dealmaking frequency 2000-2007
- Figure 154: Novartis - recent deals (2005-2008) by deal type
- Figure 155: Novartis - recent deals (2005 - 2008) by stage of development
- Figure 156: Novartis - recent deals (2005 - 2008) by therapy area
- Figure 157: Recent Novartis partnering deals (2003-2008) where contract
document available
- Figure 158: Novo Nordisk - Dealmaking frequency 2000-2007
- Figure 159: Novo Nordisk - recent deals (2005-2008) by deal type
- Figure 160: Novo Nordisk - recent deals (2005 - 2008) by stage of
development
- Figure 161: Novo Nordisk - recent deals (2005 - 2008) by therapy area
- Figure 162: Recent Novo Nordisk partnering deals (2003-2008) where
contract document available
- Figure 163: Nycomed - Dealmaking frequency 2000-2007
- Figure 164: Nycomed - recent deals (2005-2008) by deal type
- Figure 165: Nycomed - recent deals (2005 - 2008) by stage of development
- Figure 166: Nycomed - recent deals (2005 - 2008) by therapy area
- Figure 167: Recent Nycomed partnering deals (2003-2008) where contract
document available
- Figure 168: Otsuka - Dealmaking frequency 2000-2007
- Figure 169: Otsuka - recent deals (2005-2008) by deal type
- Figure 170: Otsuka - recent deals (2005 - 2008) by stage of development
- Figure 171: Otsuka - recent deals (2005 - 2008) by therapy area
- Figure 172: Recent Otsuka partnering deals (2003-2008) where contract
document available
- Figure 173: Pfizer - Dealmaking frequency 2000-2007
- Figure 174: Pfizer - recent deals (2005-2008) by deal type
- Figure 175: Pfizer - recent deals (2005 - 2008) by stage of development
- Figure 176: Pfizer - recent deals (2005 - 2008) by therapy area
- Figure 177: Recent Pfizer partnering deals (2003-2008) where contract
document available
- Figure 178: Procter & Gamble - Dealmaking frequency 2000-2007
- Figure 179: Procter & Gamble - recent deals (2005-2008) by deal type
- Figure 180: Procter & Gamble - recent deals (2005 - 2008) by stage of
development
- Figure 181: Procter & Gamble - recent deals (2005 - 2008) by therapy area
- Figure 182: Recent Procter & Gamble partnering deals (2003-2008) where
contract document available
- Figure 208: Ratiopharm - Dealmaking frequency 2000-2007
- Figure 219: Ratiopharm - recent deals (2005-2008) by deal type
- Figure 220: Ratiopharm - recent deals (2005 - 2008) by stage of
development
- Figure 221: Ratiopharm - recent deals (2005 - 2008) by therapy area
- Figure 222: Recent Ratiopharm partnering deals (2003-2008) where contract
document available
- Figure 183: Roche - Dealmaking frequency 2000-2007
- Figure 184: Roche - recent deals (2005-2008) by deal type
- Figure 185: Roche - recent deals (2005 - 2008) by stage of development
- Figure 186: Roche - recent deals (2005 - 2008) by therapy area
- Figure 187: Recent Roche partnering deals (2003-2008) where contract
document available
- Figure 188: Sanofi-Aventis - Dealmaking frequency 2000-2007
- Figure 189: Sanofi-Aventis - recent deals (2005-2008) by deal type
- Figure 190: Sanofi-Aventis - recent deals (2005 - 2008) by stage of
development
- Figure 191: Sanofi-Aventis - recent deals (2005 - 2008) by therapy area
- Figure 192: Recent Sanofi-Aventis partnering deals (2003-2008) where
contract document available
- Figure 193: Schering Plough - Dealmaking frequency 2000-2007
- Figure 194: Schering Plough - recent deals (2005-2008) by deal type
- Figure 195: Schering Plough - recent deals (2005 - 2008) by stage of
development
- Figure 196: Schering Plough - recent deals (2005 - 2008) by therapy area
- Figure 197: Recent Schering Plough partnering deals (2003-2008) where
contract document available
- Figure 208: Servier - Dealmaking frequency 2000-2007
- Figure 219: Servier - recent deals (2005-2008) by deal type
- Figure 220: Servier - recent deals (2005 - 2008) by stage of development
- Figure 221: Servier - recent deals (2005 - 2008) by therapy area
- Figure 222: Recent Servier partnering deals (2003-2008) where contract
document available
- Figure 198: Shire - Dealmaking frequency 2000-2007
- Figure 199: Shire - recent deals (2005-2008) by deal type
- Figure 200: Shire - recent deals (2005 - 2008) by stage of development
- Figure 201: Shire - recent deals (2005 - 2008) by therapy area
- Figure 202: Recent Shire partnering deals (2003-2008) where contract
document available
- Figure 203: Solvay - Dealmaking frequency 2000-2007
- Figure 204: Solvay - recent deals (2005-2008) by deal type
- Figure 205: Solvay - recent deals (2005 - 2008) by stage of development
- Figure 206: Solvay - recent deals (2005 - 2008) by therapy area
- Figure 207: Recent Solvay partnering deals (2003-2008) where contract
document available
- Figure 208: Stada - Dealmaking frequency 2000-2007
- Figure 219: Stada - recent deals (2005-2008) by deal type
- Figure 220: Stada - recent deals (2005 - 2008) by stage of development
- Figure 221: Stada - recent deals (2005 - 2008) by therapy area
- Figure 222: Recent Stada partnering deals (2003-2008) where contract
document available
- Figure 208: Takeda - Dealmaking frequency 2000-2007
- Figure 209: Takeda - recent deals (2005-2008) by deal type
- Figure 210: Takeda - recent deals (2005 - 2008) by stage of development
- Figure 211: Takeda - recent deals (2005 - 2008) by therapy area
- Figure 212: Recent Takeda partnering deals (2003-2008) where contract
document available
- Figure 208: Teva - Dealmaking frequency 2000-2007
- Figure 219: Teva - recent deals (2005-2008) by deal type
- Figure 220: Teva - recent deals (2005 - 2008) by stage of development
- Figure 221: Teva - recent deals (2005 - 2008) by therapy area
- Figure 222: Recent Teva partnering deals (2003-2008) where contract
document available
- Figure 213: UCB Group - Dealmaking frequency 2000-2007
- Figure 214: UCB Group - recent deals (2005-2008) by deal type
- Figure 215: UCB Group - recent deals (2005 - 2008) by stage of development
- Figure 216: UCB Group - recent deals (2005 - 2008) by therapy area
- Figure 217: Recent UCB Group partnering deals (2003-2008) where contract
document available
- Figure 218: Watson - Dealmaking frequency 2000-2007
- Figure 219: Watson - recent deals (2005-2008) by deal type
- Figure 220: Watson - recent deals (2005 - 2008) by stage of development
- Figure 221: Watson - recent deals (2005 - 2008) by therapy area
- Figure 222: Recent Watson partnering deals (2003-2008) where contract
document available
- Figure 223: Wyeth - Dealmaking frequency 2000-2007
- Figure 224: Wyeth - recent deals (2005-2008) by deal type
- Figure 225: Wyeth - recent deals (2005 - 2008) by stage of development
- Figure 226: Wyeth - recent deals (2005 - 2008) by therapy area
- Figure 227: Recent Wyeth partnering deals (2003-2008) where contract
document available
- Figure 228: Online partnering resources
- Figure 229: Development and license agreement between Boehringer Ingelheim
and Inspire Pharmaceuticals, February 2006
